Treatment of post-menopausal osteoporosis: beyond bisphosphonates

[1]  Oar,et al.  Key facts and figures , 2015 .

[2]  Shi-gui Yan,et al.  Alendronate versus Raloxifene for Postmenopausal Women: A Meta-Analysis of Seven Head-to-Head Randomized Controlled Trials , 2014, International journal of endocrinology.

[3]  M. Almeida,et al.  The role of estrogen and androgen receptors in bone health and disease , 2013, Nature Reviews Endocrinology.

[4]  Hang Lee,et al.  Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial , 2013, The Lancet.

[5]  S. Polyzos,et al.  Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial. , 2013, The Journal of clinical endocrinology and metabolism.

[6]  R. Zhu,et al.  Serum β-Catenin Levels Associated with the Ratio of RANKL/OPG in Patients with Postmenopausal Osteoporosis , 2013, International journal of endocrinology.

[7]  M. Almeida,et al.  Estrogen receptor-α signaling in osteoblast progenitors stimulates cortical bone accrual. , 2013, The Journal of clinical investigation.

[8]  F. Saad,et al.  Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. , 2012, European journal of cancer.

[9]  I. Fogelman,et al.  Clinical role of bisphosphonate therapy , 2012, International journal of women's health.

[10]  K. Lippuner.  The future of osteoporosis treatment - a research update. , 2012, Swiss medical weekly.

[11]  R. Pacifici.  Role of T cells in ovariectomy induced bone loss—revisited , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  R. Baron,et al.  Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. , 2012, The Journal of clinical endocrinology and metabolism.

[13]  Lynda F. Bonewald,et al.  Sclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway , 2011, PloS one.

[14]  F. Kianifard,et al.  Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density , 2011, Menopause.

[15]  T. Spector,et al.  Safety and efficacy of the cathepsin K inhibitor ONO‐5334 in postmenopausal osteoporosis: The OCEAN study , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  T. Rachner,et al.  Osteoporosis: now and the future , 2011, The Lancet.

[17]  L. Hocking,et al.  Bone remodelling at a glance , 2011, Journal of Cell Science.

[18]  P. Croucher,et al.  Glycogen synthase kinase‐3α/β inhibition promotes in vivo amplification of endogenous mesenchymal progenitors with osteogenic and adipogenic potential and their differentiation to the osteogenic lineage , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  S. Cummings,et al.  Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. , 2011, The Journal of clinical endocrinology and metabolism.

[20]  E. Posvar,et al.  Single‐dose, placebo‐controlled, randomized study of AMG 785, a sclerostin monoclonal antibody , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  E. Eriksen,et al.  Cellular mechanisms of bone remodeling , 2010, Reviews in Endocrine and Metabolic Disorders.

[22]  Klaus Klaushofer,et al.  Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[23]  M. Horowitz,et al.  How B cells influence bone biology in health and disease. , 2010, Bone.

[24]  P. Batur,et al.  Profile of teriparatide in the management of postmenopausal osteoporosis , 2010, International journal of women's health.

[25]  S. Malozowski.  Lasofoxifene for postmenopausal women with osteoporosis. , 2010, The New England journal of medicine.

[26]  R. Weinstein,et al.  Continuous Elevation of PTH Increases the Number of Osteoblasts via Both Osteoclast-Dependent and -Independent Mechanisms , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  S. Tetradis,et al.  Osteonecrosis of the jaw in a patient on Denosumab. , 2010, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[28]  Jacques P. Brown,et al.  Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  J. Eisman,et al.  Odanacatib, a cathepsin‐K inhibitor for osteoporosis: A two‐year study in postmenopausal women with low bone density , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[30]  Claus Christiansen,et al.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.

[31]  F. Saad,et al.  Denosumab in men receiving androgen-deprivation therapy for prostate cancer. , 2009, The New England journal of medicine.

[32]  R. Recker,et al.  Comparative Effects of Teriparatide and Strontium Ranelate on Bone Biopsies and Biochemical Markers of Bone Turnover in Postmenopausal Women With Osteoporosis , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  David M. Thomas,et al.  Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. , 2009, The Journal of clinical investigation.

[34]  Qing Chen,et al.  Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[35]  J. Shaughnessy,et al.  Inhibiting Dickkopf‐1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[36]  P. Roschger,et al.  Treatment of Osteoporosis with Parathyroid Hormone and Teriparatide , 2009, Calcified Tissue International.

[37]  J. Ryaby,et al.  Thrombin related peptide TP508 promoted fracture repair in a mouse high energy fracture model , 2009, Journal of orthopaedic surgery and research.

[38]  Jacques P. Brown,et al.  Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[39]  S. Khosla,et al.  Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate , 2008, Proceedings of the National Academy of Sciences.

[40]  N. Sims,et al.  Cardiotrophin‐1 Is an Osteoclast‐Derived Stimulus of Bone Formation Required for Normal Bone Remodeling , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[41]  Chenbei Chang,et al.  Parathyroid hormone signaling through low-density lipoprotein-related protein 6. , 2008, Genes & development.

[42]  R. Chlebowski,et al.  Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  G. Dalsky,et al.  Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study* , 2008, Current medical research and opinion.

[44]  H. Blum,et al.  OPG Is Regulated by β-Catenin and Mediates Resistance to TRAIL-Induced Apoptosis in Colon Cancer , 2008, Clinical Cancer Research.

[45]  J. S. San Martin,et al.  Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. , 2008, Bone.

[46]  G. Girolomoni,et al.  Drug-induced morphea: report of a case induced by balicatib and review of the literature. , 2008, Journal of the American Academy of Dermatology.

[47]  S. Brianza,et al.  Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. , 2008, Bone.

[48]  S. Boonen,et al.  Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. , 2008, The Journal of clinical endocrinology and metabolism.

[49]  J. Carroll,et al.  Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival , 2008, The EMBO journal.

[50]  Jennifer J Westendorf,et al.  Building bone to reverse osteoporosis and repair fractures. , 2008, The Journal of clinical investigation.

[51]  J. Falgueyret,et al.  The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. , 2008, Bioorganic & medicinal chemistry letters.

[52]  S. Boonen,et al.  Zoledronic acid and clinical fractures and mortality after hip fracture. , 2007, The New England journal of medicine.

[53]  S. Silverman,et al.  Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[54]  P. Chambon,et al.  Estrogen Prevents Bone Loss via Estrogen Receptor α and Induction of Fas Ligand in Osteoclasts , 2007, Cell.

[55]  C. O’Brien,et al.  A Novel Ligand-independent Function of the Estrogen Receptor Is Essential for Osteocyte and Osteoblast Mechanotransduction* , 2007, Journal of Biological Chemistry.

[56]  R. Baron,et al.  Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. , 2007, Endocrinology.

[57]  S. Cummings,et al.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. , 2007, The New England journal of medicine.

[58]  D. Dempster,et al.  New Observations on Bone Quality in Mild Primary Hyperparathyroidism as Determined by Quantitative Backscattered Electron Imaging , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[59]  Georg Schett,et al.  Dickkopf-1 is a master regulator of joint remodeling , 2007, Nature Medicine.

[60]  R. Marcus,et al.  Osteosarcoma and Teriparatide? , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[61]  C. Lengner,et al.  Networks and hubs for the transcriptional control of osteoblastogenesis , 2006, Reviews in Endocrine and Metabolic Disorders.

[62]  A. McMahon,et al.  Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors , 2006, Development.

[63]  A. Pitsillides,et al.  Osteocytes Use Estrogen Receptor α to Respond to Strain but Their ERα Content Is Regulated by Estrogen , 2006 .

[64]  E. Barrett-Connor,et al.  Adult Weight Change and Risk of Postmenopausal Breast Cancer , 2006, The New England journal of medicine.

[65]  U. Lerner,et al.  Bone Remodeling in Post-menopausal Osteoporosis , 2006, Journal of dental research.

[66]  S. Boonen,et al.  Strontium Ranelate Reduces the Risk of Vertebral and Nonvertebral Fractures in Women Eighty Years of Age and Older , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[67]  J. Street,et al.  Vascular endothelial growth factor regulates osteoblast survival – evidence for an autocrine feedback mechanism , 2009, Journal of orthopaedic surgery and research.

[68]  P. Miller,et al.  Denosumab in Postmenopausal Women with Low Bone Mineral Density , 2007 .

[69]  Maria Luisa Brandi,et al.  Vascular Biology and the Skeleton , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[70]  A. Díez-Pérez,et al.  Anti-vertebral fracture efficacy of raloxifene: a meta-analysis , 2006, Osteoporosis International.

[71]  K. Tsai,et al.  Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis , 2006, Osteoporosis International.

[72]  L. Lanier,et al.  Role of ITAM‐containing adapter proteins and their receptors in the immune system and bone , 2005, Immunological reviews.

[73]  G. Dalsky,et al.  Sustained Nonvertebral Fragility Fracture Risk Reduction After Discontinuation of Teriparatide Treatment , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[74]  M. Kneissel,et al.  SOST is a target gene for PTH in bone. , 2005, Bone.

[75]  D. Bauer,et al.  Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. , 2005, Endocrine reviews.

[76]  E. Lewiecki,et al.  Early Changes in Biochemical Markers of Bone Formation Predict BMD Response to Teriparatide in Postmenopausal Women With Osteoporosis , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[77]  Peng Liu,et al.  Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling* , 2005, Journal of Biological Chemistry.

[78]  B. Ettinger,et al.  Differential Effects of Teriparatide on BMD After Treatment With Raloxifene or Alendronate , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[79]  C. Barnstable,et al.  Osteoblasts and osteoclasts express PEDF, VEGF-A isoforms, and VEGF receptors: possible mediators of angiogenesis and matrix remodeling in the bone. , 2004, Biochemical and biophysical research communications.

[80]  L. Qin,et al.  Parathyroid hormone: a double-edged sword for bone metabolism , 2004, Trends in Endocrinology & Metabolism.

[81]  Kwan Tat Steeve,et al.  IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. , 2004 .

[82]  D. McDonnell.  Mining the complexities of the estrogen signaling pathways for novel therapeutics. , 2003, Endocrinology.

[83]  A. LaCroix,et al.  Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. , 2003, JAMA.

[84]  J. Finkelstein,et al.  The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. , 2003, The New England journal of medicine.

[85]  Mary L Bouxsein,et al.  The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. , 2003, The New England journal of medicine.

[86]  Yoshiaki Kawano,et al.  Secreted antagonists of the Wnt signalling pathway , 2003, Journal of Cell Science.

[87]  Hans Clevers,et al.  Caught up in a Wnt storm: Wnt signaling in cancer. , 2003, Biochimica et biophysica acta.

[88]  M. Lübbert,et al.  Upstream and downstream targets of RUNX proteins , 2003, Journal of cellular biochemistry.

[89]  J. Hoover,et al.  New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. , 2003, Endocrinology.

[90]  P. Kulkarni,et al.  A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. , 2002, The Journal of clinical endocrinology and metabolism.

[91]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[92]  M. Zaidi,et al.  Forty years of calcitonin--where are we now? A tribute to the work of Iain Macintyre, FRS. , 2002, Bone.

[93]  J. Vahle,et al.  Skeletal Changes in Rats Given Daily Subcutaneous Injections of Recombinant Human Parathyroid Hormone (1-34) for 2 Years and Relevance to Human Safety , 2002, Toxicologic pathology.

[94]  W. Puhl,et al.  Vascular endothelial growth factor stimulates chemotactic migration of primary human osteoblasts. , 2002, Bone.

[95]  S. Khosla,et al.  Minireview: the OPG/RANKL/RANK system. , 2001, Endocrinology.

[96]  L. Norton,et al.  The MORE Trial: Multiple Outcomes for Raloxifene Evaluation , 2001, Annals of the New York Academy of Sciences.

[97]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.

[98]  R. Lindsay,et al.  Parathyroid Hormone Added to Established Hormone Therapy: Effects on Vertebral Fracture and Maintenance of Bone Mass After Parathyroid Hormone Withdrawal , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[99]  D. Agnusdei,et al.  Raloxifene: results from the MORE study. , 2000, Journal of musculoskeletal & neuronal interactions.

[100]  S. Cummings,et al.  Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. , 2000, The Journal of clinical endocrinology and metabolism.

[101]  R. Pacifici.  Aging and Cytokine Production , 1999, Calcified Tissue International.

[102]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[103]  H. Genant,et al.  Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. , 1998, The Journal of clinical investigation.

[104]  R. Lindsay,et al.  Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis , 1997, The Lancet.

[105]  A. Phillips.  The Fracture Intervention Trial , 1997, The Lancet.

[106]  F. Ross,et al.  Estrogen Deficiency Increases the Ability of Stromal Cells to Support Murine Osteoclastogenesis via an Interleukin-1and Tumor Necrosis Factor-mediated Stimulation of Macrophage Colony-stimulating Factor Production* , 1996, The Journal of Biological Chemistry.

[107]  B. Gelb,et al.  Pycnodysostosis, a Lysosomal Disease Caused by Cathepsin K Deficiency , 1996, Science.

[108]  G. Passeri,et al.  17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. , 1992, The Journal of clinical investigation.

[109]  F. Vescini,et al.  PTH 1-84: bone rebuilding as a target for the therapy of severe osteoporosis. , 2012, Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases.

[110]  T. Spector,et al.  Efficacy and safety of the cathepsin K inhibitor, ONO-5334, and alendronate on post-menopausal osteopenia or osteoporosis: 2-year results from the ocean study , 2011 .

[111]  P. Chambon,et al.  Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. , 2007, Cell.

[112]  D. Felsenberg,et al.  Effect of raloxifene after recombinant teriparatide [hPTH(1–34)] treatment in postmenopausal women with osteoporosis , 2007, Osteoporosis International.

[113]  A. Pitsillides,et al.  Osteocytes use estrogen receptor alpha to respond to strain but their ERalpha content is regulated by estrogen. , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[114]  H. Frost.  Tetracycline-based histological analysis of bone remodeling , 2005, Calcified Tissue Research.

[115]  S. Kwan Tat,et al.  IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. , 2004, Cytokine & growth factor reviews.

[116]  N. Lane,et al.  Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis , 2003, Osteoporosis International.

[117]  R. L. Cain,et al.  Printed in U.S.A. Copyright © 2001 by The Endocrine Society Catabolic Effects of Continuous Human PTH (1–38) in Vivo Is Associated with Sustained Stimulation of RANKL and Inhibition of Osteoprotegerin and Gene-Associated Bone Formation , 2022 .

[118]  Harry K. Genant,et al.  Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial , 2000 .